Hennion & Walsh Asset Management Inc. Acquires 7,500 Shares of Boston Scientific Co. (NYSE:BSX)

Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 7.0% in the first quarter, according to its most recent filing with the SEC. The firm owned 114,840 shares of the medical equipment provider's stock after acquiring an additional 7,500 shares during the period. Hennion & Walsh Asset Management Inc.'s holdings in Boston Scientific were worth $11,585,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Brighton Jones LLC lifted its stake in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after buying an additional 226 shares during the period. Union Bancaire Privee UBP SA bought a new stake in shares of Boston Scientific in the 4th quarter valued at about $33,074,000. Tokio Marine Asset Management Co. Ltd. raised its position in shares of Boston Scientific by 5.6% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 44,233 shares of the medical equipment provider's stock valued at $3,951,000 after acquiring an additional 2,348 shares during the period. Tritonpoint Wealth LLC boosted its stake in Boston Scientific by 10.1% during the 4th quarter. Tritonpoint Wealth LLC now owns 3,040 shares of the medical equipment provider's stock worth $271,000 after acquiring an additional 279 shares during the last quarter. Finally, DAVENPORT & Co LLC lifted its holdings in Boston Scientific by 5.0% during the fourth quarter. DAVENPORT & Co LLC now owns 11,829 shares of the medical equipment provider's stock worth $1,057,000 after acquiring an additional 561 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Insider Activity at Boston Scientific

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of Boston Scientific stock in a transaction on Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the transaction, the senior vice president now directly owns 36,193 shares of the company's stock, valued at $3,441,592.37. The trade was a 11.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the sale, the chief executive officer now directly owns 1,476,882 shares of the company's stock, valued at $153,137,894.58. The trade was a 10.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 355,598 shares of company stock valued at $36,607,141. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Down 0.7%

Boston Scientific stock traded down $0.69 during mid-day trading on Wednesday, reaching $102.41. The stock had a trading volume of 5,681,928 shares, compared to its average volume of 6,442,604. The firm has a market capitalization of $151.51 billion, a PE ratio of 81.93, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a fifty-two week low of $71.88 and a fifty-two week high of $107.17. The stock's 50-day simple moving average is $100.38 and its 200-day simple moving average is $98.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The company had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Boston Scientific's quarterly revenue was up 20.9% compared to the same quarter last year. During the same period last year, the business earned $0.56 EPS. On average, sell-side analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on BSX shares. Needham & Company LLC restated a "buy" rating and issued a $115.00 price target on shares of Boston Scientific in a report on Wednesday, May 28th. Evercore ISI upped their price target on shares of Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Raymond James boosted their target price on shares of Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research report on Thursday, February 6th. Wall Street Zen raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Finally, Robert W. Baird upped their price objective on Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Twenty-one investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of "Buy" and a consensus price target of $116.00.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.